• 111
  • 4
  • Favorite

BeiGene Shares Rise After Q2 Revenue More Than Doubles Y/Y

seekingalpha2022-08-04

U.S.-listed shares of BeiGene rose as much as 3% to $174.72 in Thursday morning trading, after the company reported Q2 revenue that more than doubled Y/Y.

BGNE stock had pared most of the gains and was last trading 1.7% higher as of 1010 ET.

BGNE's quarterly revenue of $341.57M rose 127.7% Y/Y and beat estimates by $30.5M. However, Q2 GAAP earnings per American depositary share of -$5.56 missed expectations by $1.45.

The bulk of BGNE's Q2 sales came from product revenue of $304.5M (vs. $138.6M last year), which included:

  • Global sales of BeiGene's (BGNE) cancer drug Brukinsa, which came in at $128.7M, a significant increase from $42.4M last year.
  • Sales of BGNE's other cancer medication, tislelizumab, of $104.9M in China, compared to $74.9M last year.
  • Sales of products in-licensed from Amgen (AMGN) of $29.5M in China vs. $3.3M a year ago.
  • Sales of products in-licensed from Bristol-Myers Squibb (BMY) of $23.4M in China, a Y/Y gain from $13.4M.

“We made significant progress in our mission to reach far more cancer patients with innovative and affordable medicines, with growth in product revenues across our portfolio, driven primarily by our internally developed medicines, Brukinsa and tislelizumab," BeiGene CEO John Oyler said in the earnings report.

Up to Wednesday's close, BGNE American depositary shares have lost 37.4% YTD.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment4

  • ericbqlee
    ·2022-08-04
    😀
    Reply
    Report
  • SPOT_ON
    ·2022-08-04
    Ok
    Reply
    Report
  • ARIESan
    ·2022-08-04
    Very nice 👍 
    Reply
    Report
  • Prakash450
    ·2022-08-04
    [Smile] 
    Reply
    Report
errorbox banner

抱歉,当前请求异常(-1)

7x24

  • 05:52

    City Developments - Suspends Trading Due to Board Disagreement

  • 05:52

    Yubico Ab : Berenberg Raises to Buy From Hold; Cuts Target Price to SEK 270 From SEK 300

  • 05:52

    United Overseas Australia Ltd FY EPS AUD 0.0558

  • 05:51

    Schneider Electric : Jefferies Raises Target Price to EUR 292 From EUR 282

  • 05:50

    Idorsia Ltd - Released From Exclusivity Constraint Regarding Global Rights to Aprocitentan - NOW Pivoting to Alternative Parties

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email:uservice@ttm.financial